×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SWTX – springworks therapeutics, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SWTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
08:23 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $60.00 price target on the stock.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $60.00 price target on the stock.
11/18
05:41 pm
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $77.00 price target on the stock.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $77.00 price target on the stock.
11/15
09:09 am
swtx
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report [Yahoo! Finance]
Low
Report
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report [Yahoo! Finance]
11/13
12:21 pm
swtx
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark [Yahoo! Finance]
Low
Report
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark [Yahoo! Finance]
11/13
02:26 am
swtx
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/12
11:33 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target lowered by analysts at HC Wainwright from $76.00 to $74.00. They now have a "buy" rating on the stock.
Low
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target lowered by analysts at HC Wainwright from $76.00 to $74.00. They now have a "buy" rating on the stock.
11/12
09:25 am
swtx
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
High
Report
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
11/12
06:30 am
swtx
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Low
Report
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
06:30 am
SWTX
springworks therapeutics, inc. - common stock
BEAT
Report
-3.4%
springworks therapeutics, inc. - common stock
8/7/2024
06:30 am
SWTX
springworks therapeutics, inc. - common stock
BEAT
Report
2.3%
springworks therapeutics, inc. - common stock
5/2/2024
06:30 am
SWTX
springworks therapeutics, inc. - common stock
BEAT
Report
-9.5%
springworks therapeutics, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
09:21 am
swtx
Form 10-Q SpringWorks Therapeutics For: Sep 30
High
Report
Form 10-Q SpringWorks Therapeutics For: Sep 30
11/12
09:21 am
swtx
Form 8-K SpringWorks Therapeutics For: Nov 12
High
Report
Form 8-K SpringWorks Therapeutics For: Nov 12
10/25
09:47 pm
swtx
Form SC 13G/A SpringWorks Therapeutics Filed by: Boxer Capital Management, LLC
Low
Report
Form SC 13G/A SpringWorks Therapeutics Filed by: Boxer Capital Management, LLC
10/3
04:26 pm
swtx
Form 4 SpringWorks Therapeutics For: Oct 02 Filed by: Lin Tai-An
Low
Report
Form 4 SpringWorks Therapeutics For: Oct 02 Filed by: Lin Tai-An
9/4
04:07 pm
swtx
Form 4 SpringWorks Therapeutics For: Sep 03 Filed by: Islam Saqib
Low
Report
Form 4 SpringWorks Therapeutics For: Sep 03 Filed by: Islam Saqib
9/4
04:06 pm
swtx
Form 4 SpringWorks Therapeutics For: Sep 03 Filed by: Edris Badreddin
Low
Report
Form 4 SpringWorks Therapeutics For: Sep 03 Filed by: Edris Badreddin
9/3
04:10 pm
swtx
Form 144 SpringWorks Therapeutics Filed by: Edris Badreddin
Medium
Report
Form 144 SpringWorks Therapeutics Filed by: Edris Badreddin
9/3
04:07 pm
swtx
Form 144 SpringWorks Therapeutics Filed by: Islam Saqib
Medium
Report
Form 144 SpringWorks Therapeutics Filed by: Islam Saqib
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
SpringWorks Therapeutics (NASDAQ: SWTX) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
15.9%
12/9 Form 8-K SpringWorks Therapeutics For: Dec 09 7.2%
2/3 SpringWorks Therapeutics (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock. 7.1%
4/14 SpringWorks Therapeutics (NASDAQ: SWTX) had its price target lowered by analysts at HC Wainwright from $60.00 to $58.00. They now have a "buy" rating on the stock. 6.9%
2/14 Form SC 13G/A SpringWorks Therapeutics Filed by: PERCEPTIVE ADVISORS LLC 5.8%
9/19 Form 4 SpringWorks Therapeutics For: Sep 17 Filed by: Pfizer Ventures (US) LLC 5.3%
12/9 Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) 4.6%
3/23 Form S-8 SpringWorks Therapeutics 4.0%
9/13 Form 424B4 SpringWorks Therapeutics 3.7%
9/26 Form SC 13G SpringWorks Therapeutics Filed by: PERCEPTIVE ADVISORS LLC 2.8%
12/9 Form 8-K SpringWorks Therapeutics For: Dec 09 7.2%
2/3 SpringWorks Therapeutics (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock. 7.1%
4/14 SpringWorks Therapeutics (NASDAQ: SWTX) had its price target lowered by analysts at HC Wainwright from $60.00 to $58.00. They now have a "buy" rating on the stock. 6.9%
2/14 Form SC 13G/A SpringWorks Therapeutics Filed by: PERCEPTIVE ADVISORS LLC 5.8%
9/19 Form 4 SpringWorks Therapeutics For: Sep 17 Filed by: Pfizer Ventures (US) LLC 5.3%
12/9 Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) 4.6%
3/23 Form S-8 SpringWorks Therapeutics 4.0%
9/13 Form 424B4 SpringWorks Therapeutics 3.7%
9/26 Form SC 13G SpringWorks Therapeutics Filed by: PERCEPTIVE ADVISORS LLC 2.8%
TOP News Decliners
3/13
Form 4 SpringWorks Therapeutics For: Mar 12 Filed by: SQUINTO STEPHEN P
-27.1%
9/25 Form SC 13D SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC -21.5%
9/12 Form 3 SpringWorks Therapeutics For: Sep 12 Filed by: Lewis-Hall Freda C -7.6%
3/4 Form 4 SpringWorks Therapeutics For: Mar 02 Filed by: Francis Perier I Jr -6.2%
1/6 SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference -5.8%
10/24 SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN) -5.7%
10/29 Form S-8 SpringWorks Therapeutics -4.7%
2/5 Form 4 SpringWorks Therapeutics For: Feb 03 Filed by: Weinstein Herschel S -4.3%
12/4 SpringWorks Therapeutics (NASDAQ: SWTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -4.0%
1/12 Here's Why SpringWorks Therapeutics Climbed 69% in December [The Motley Fool] -3.2%
9/25 Form SC 13D SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC -21.5%
9/12 Form 3 SpringWorks Therapeutics For: Sep 12 Filed by: Lewis-Hall Freda C -7.6%
3/4 Form 4 SpringWorks Therapeutics For: Mar 02 Filed by: Francis Perier I Jr -6.2%
1/6 SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference -5.8%
10/24 SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN) -5.7%
10/29 Form S-8 SpringWorks Therapeutics -4.7%
2/5 Form 4 SpringWorks Therapeutics For: Feb 03 Filed by: Weinstein Herschel S -4.3%
12/4 SpringWorks Therapeutics (NASDAQ: SWTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -4.0%
1/12 Here's Why SpringWorks Therapeutics Climbed 69% in December [The Motley Fool] -3.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: